

# Manuel Ramos-Casals

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/339579/manuel-ramos-casals-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

324  
papers

19,497  
citations

76  
h-index

128  
g-index

382  
ext. papers

23,566  
ext. citations

4.9  
avg, IF

6.57  
L-index

#	Paper	IF	Citations
324	Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. <i>Medicine (United States)</i> , <b>2003</b> , 82, 299-308	1.8	863
323	Adult haemophagocytic syndrome. <i>Lancet, The</i> , <b>2014</b> , 383, 1503-1516	40	698
322	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 20-8	2.4	645
321	Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. <i>Medicine (United States)</i> , <b>2007</b> , 86, 242-251	1.8	493
320	The cryoglobulinaemias. <i>Lancet, The</i> , <b>2012</b> , 379, 348-60	40	358
319	Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. <i>Medicine (United States)</i> , <b>2008</b> , 87, 210-219	1.8	358
318	Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. <i>Medicine (United States)</i> , <b>2001</b> , 80, 355-77	1.8	281
317	Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. <i>Medicine (United States)</i> , <b>2002</b> , 81, 270-80	1.8	279
316	Sjögren syndrome. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16047	51.1	267
315	EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 968-72	2.4	264
314	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
313	Autoimmune diseases induced by biological agents: a double-edged sword?. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 188-93	13.6	245
312	Treatment of primary Sjögren syndrome: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 452-60	27.4	240
311	Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. <i>Lupus</i> , <b>2009</b> , 18, 767-76	2.6	237
310	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 38	51.1	234
309	Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2568-76		229
308	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210

307	Autoimmune diseases induced by TNF-targeted therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2008</b> , 22, 847-61	5.3	208
306	Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. <i>Medicine (United States)</i> , <b>2011</b> , 90, 359-371	1.8	203
305	Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. <i>Medicine (United States)</i> , <b>2001</b> , 80, 252-62	1.8	199
304	Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. <i>Annals of the Rheumatic Diseases</i> , <b>1998</b> , 57, 456-9	2.4	194
303	The clinical spectrum of IgG4-related disease. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 1203-10	13.6	192
302	Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 256-64	5.3	190
301	Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 529-35	2.4	184
300	Primary Sjögren's syndrome: new clinical and therapeutic concepts. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 347-54	2.4	183
299	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 357-64	13.6	176
298	Primary Sjogren syndrome. <i>BMJ, The</i> , <b>2012</b> , 344, e3821	5.9	166
297	Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1205-9	2.4	155
296	Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. <i>Lupus</i> , <b>2006</b> , 15, 584-9	2.6	151
295	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , <b>2015</b> , 54, 2230-8	3.9	150
294	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , <b>2015</b> , 1, e000022	5.9	150
293	Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. <i>Medicine (United States)</i> , <b>2004</b> , 83, 96-106	1.8	147
292	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 382-9	2.4	144
291	The clinical spectrum of autoimmune congenital heart block. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 301-12	8.1	140
290	Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. <i>Medicine (United States)</i> , <b>2006</b> , 85, 95-104	1.8	140

289	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 3-18	2.4	139
288	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 859-66	2.4	138
287	Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. <i>Medicine (United States)</i> , <b>2005</b> , 84, 81-89	1.8	138
286	Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 89-94		136
285	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 1312-7	2.4	127
284	Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). <i>Rheumatology</i> , <b>2014</b> , 53, 321-31	3.9	125
283	Topical and systemic medications for the treatment of primary Sjögren's syndrome. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 399-411	8.1	123
282	Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. <i>Medicine (United States)</i> , <b>2005</b> , 84, 69-80	1.8	123
281	Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. <i>Lupus</i> , <b>2008</b> , 17, 281-8	2.6	120
280	Diagnostic Approach to the Complexity of IgG4-Related Disease. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 927-39	3.4	119
279	Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases. <i>Medicine (United States)</i> , <b>2001</b> , 80, 1-8	1.8	117
278	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
277	Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. <i>Rheumatology</i> , <b>2007</b> , 46, 1359-62	3.9	114
276	Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. <i>Seminars in Arthritis and Rheumatism</i> , <b>2004</b> , 33, 217-30	5.3	114
275	Biologics-induced autoimmune diseases. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 56-64	5.3	113
274	A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. <i>Medicine (United States)</i> , <b>2008</b> , 87, 345-364	1.8	112
273	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1726-32	2.4	111
272	Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1442-8	4.1	107

271	Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. <i>Medicine (United States)</i> , <b>2008</b> , 87, 311-318	1.8	107
270	Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 35, 322-32	5.3	106
269	Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 348-55	2.4	102
268	Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , <b>2006</b> , 5, 180-6	13.6	99
267	Google-driven search for big data in autoimmune geoeidemiology: analysis of 394,827 patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 670-9	13.6	96
266	The overlap of Sjögren's syndrome with other systemic autoimmune diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2007</b> , 36, 246-55	5.3	96
265	Monoclonal antibody therapy-associated neurological disorders. <i>Nature Reviews Neurology</i> , <b>2011</b> , 7, 165-72	17.2	95
264	Primary Sjögren syndrome: hematologic patterns of disease expression. <i>Medicine (United States)</i> , <b>2002</b> , 81, 281-92	1.8	93
263	Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. <i>Lupus</i> , <b>2003</b> , 12, 341-55	2.6	92
262	Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 200-5	5.3	90
261	Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 35, 312-21	5.3	84
260	Primary Sjögren's syndrome: current and emergent aetiopathogenic concepts. <i>Rheumatology</i> , <b>2005</b> , 44, 1354-67	3.9	84
259	Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. <i>Annals of the Rheumatic Diseases</i> , <b>2003</b> , 62, 431-4	2.4	84
258	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 137-56	5.1	83
257	Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2010</b> , 28, 468-76	2.2	81
256	Therapeutic targeting of B cells for rheumatic autoimmune diseases. <i>Pharmacological Reviews</i> , <b>2011</b> , 63, 127-56	22.5	80
255	Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 36, 189-96	5.3	78
254	Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 2801-6		78

253	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
252	Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 91-101	4	77
251	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 11	51.1	76
250	Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. <i>Medicine (United States)</i> , <b>2003</b> , 82, 87-96	1.8	76
249	Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 8-15	13.6	76
248	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 575-583.e1	6.9	75
247	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1042-1050	2.4	73
246	Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 476-8	2.4	73
245	Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 90	22.4	72
244	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 1255-1271	4.1	72
243	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 740-6	2.4	72
242	Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>1999</b> , 28, 326-32	5.3	72
241	Thyroid disease in Sjögren's syndrome. <i>Clinical Rheumatology</i> , <b>2007</b> , 26, 1601-6	3.9	70
240	Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients. <i>Clinical Rheumatology</i> , <b>2006</b> , 25, 341-6	3.9	70
239	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 1145-1160	13.6	69
238	Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. <i>Seminars in Arthritis and Rheumatism</i> , <b>2012</b> , 41, 789-800	5.3	69
237	Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. <i>Autoimmunity Reviews</i> , <b>2006</b> , 6, 72-5	13.6	69
236	Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2001</b> , 30, 366-73	5.3	69

235	Systemic and organ-specific immune-related manifestations of COVID-19. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 315-332	8.1	67
234	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 523-541	13.6	66
233	Young onset of primary Sjögren's syndrome: clinical and immunological characteristics. <i>Lupus</i> , <b>1998</b> , 7, 202-6	2.6	66
232	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
231	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1308-14	2.4	65
230	Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 1009-16	11.6	63
229	Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 161-70		62
228	Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. <i>Journal of Internal Medicine</i> , <b>2005</b> , 257, 549-57	10.8	61
227	Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 943-6	2.4	60
226	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1282-1299	13.4	58
225	B-cell-depleting therapy in systemic lupus erythematosus. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 327-364		58
224	Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. <i>Lupus</i> , <b>2010</b> , 19, 941-8	2.6	58
223	Mixed cryoglobulinemia: new concepts. <i>Lupus</i> , <b>2000</b> , 9, 83-91	2.6	57
222	Thyroid disease in primary Sjögren syndrome. Study in a series of 160 patients. <i>Medicine (United States)</i> , <b>2000</b> , 79, 103-8	1.8	56
221	Outcome measures for primary Sjögren's syndrome: a comprehensive review. <i>Journal of Autoimmunity</i> , <b>2014</b> , 51, 51-6	15.5	55
220	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , <b>2014</b> , 53, 2209-13	3.9	55
219	Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes. <i>Journal of Autoimmunity</i> , <b>2012</b> , 39, 43-8	15.5	55
218	Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. <i>Seminars in Arthritis and Rheumatism</i> , <b>2007</b> , 36, 287-96	5.3	54



217	Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. <i>Lupus</i> , <b>2004</b> , 13, 777-83	2.6	54
216	Cardiovascular risk factors and the long-term outcome of lupus nephritis. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2001</b> , 94, 19-26	2.7	54
215	Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. <i>Medicine (United States)</i> , <b>2013</b> , 92, 273-284	1.8	53
214	Sarcoidosis or Sjögren syndrome? Clues to defining mimicry or coexistence in 59 cases. <i>Medicine (United States)</i> , <b>2004</b> , 83, 85-95	1.8	53
213	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
212	Advances in the understanding and treatment of systemic complications in Sjögren's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 520-7	5.3	50
211	Primary Sjögren's syndrome in the elderly: clinical and immunological characteristics. <i>Lupus</i> , <b>1999</b> , 8, 20-3	2.6	50
210	IgG4-related disease: Advances in the diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2016</b> , 30, 261-278	5.3	49
209	Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. <i>Lupus</i> , <b>2000</b> , 9, 584-8	2.6	49
208	Antineutrophil cytoplasmic antibodies in primary Sjögren's syndrome: prevalence and clinical significance. <i>British Journal of Rheumatology</i> , <b>1998</b> , 37, 1287-91		49
207	Vasculitis induced by tumor necrosis factor-targeted therapies. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 442-8	4.9	48
206	The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 81-6	2.4	48
205	Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 95-9		47
204	Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 726-30	4.1	47
203	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
202	Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R112	5.7	46
201	Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 386-94	2.4	45
200	The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome. <i>British Journal of Rheumatology</i> , <b>2002</b> , 41, 1025-30		44



199	Sjögren's syndrome and hepatitis C virus. <i>Clinical Rheumatology</i> , <b>1999</b> , 18, 93-100	3.9	44
198	Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1552-7	4.1	44
197	Cytopenia and past human parvovirus B19 infection in patients with primary Sjögren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2000</b> , 29, 373-8	5.3	43
196	Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1281-2		42
195	Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. <i>Medicine (United States)</i> , <b>2010</b> , 89, 300-307	1.8	41
194	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1945-1950	2.4	41
193	Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. <i>Rheumatology</i> , <b>2016</b> , 55, 1443-51	3.9	41
192	Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 391-9	5.3	40
191	Outcome measures for primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , <b>2012</b> , 39, 97-102	15.5	40
190	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000143	4.6	40
189	Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjogren's syndrome. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 585-90	4.1	39
188	SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 961-7	2.4	39
187	Emerging biological therapies in primary Sjogren's syndrome. <i>Rheumatology</i> , <b>2007</b> , 46, 1389-96	3.9	39
186	Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. <i>British Journal of Rheumatology</i> , <b>2004</b> , 43, 1454-6		39
185	Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2005</b> , 23, 351-6	2.2	39
184	Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 279-89	4	38
183	Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2007</b> , 46, 76-80	3.9	38
182	Nodular regenerative hyperplasia of the liver and antiphospholipid antibodies: report of two cases and review of the literature. <i>Lupus</i> , <b>1999</b> , 8, 160-3	2.6	38

181	Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 495-9	4.1	38
180	High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 754-61	4.1	38
179	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. <i>Lupus</i> , <b>2017</b> , 26, 1051-1059	2.6	37
178	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
177	Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients. <i>Medicine (United States)</i> , <b>2005</b> , 84, 90-97	1.8	35
176	Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. <i>Clinical and Experimental Rheumatology</i> , <b>2001</b> , 19, 411-5	2.2	35
175	Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2003</b> , 33, 19-28	5.3	34
174	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000163	4.6	34
173	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 102-112	2.2	34
172	High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2001</b> , 40, 1056-9	3.9	33
171	Primary Sjögren's syndrome in men: clinical and immunological characteristics. <i>Lupus</i> , <b>2000</b> , 9, 61-4	2.6	33
170	Autoimmune congenital heart block: complex and unusual situations. <i>Lupus</i> , <b>2016</b> , 25, 116-28	2.6	32
169	B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 646-52	13.6	32
168	Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 974648		32
167	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 128-35	4.7	31
166	Rituximab therapy in lupus nephritis: current clinical evidence. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2011</b> , 40, 159-69	12.3	31
165	Th1/Th2 cytokine imbalance in patients with Sjögren syndrome secondary to hepatitis C virus infection. <i>Seminars in Arthritis and Rheumatism</i> , <b>2002</b> , 32, 56-63	5.3	31
164	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31

163	Catastrophic antiphospholipid syndrome: clinical description and triggering factors in 8 patients. <i>Journal of Rheumatology</i> , <b>2000</b> , 27, 238-40	4.1	31
162	Viral etiopathogenesis of Sjögren's syndrome: role of the hepatitis C virus. <i>Autoimmunity Reviews</i> , <b>2002</b> , 1, 238-43	13.6	30
161	Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. <i>British Journal of Rheumatology</i> , <b>2003</b> , 42, 818-28		29
160	Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. <i>Lupus</i> , <b>2004</b> , 13, 969-71	2.6	29
159	Prognostic markers of lymphoma development in primary Sjögren syndrome. <i>Lupus</i> , <b>2019</b> , 28, 923-936	2.6	28
158	Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2009</b> , 38, 389-95	5.3	28
157	Sjögren syndrome or sjögren disease? The histological and immunological bias caused by the 2002 criteria. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2010</b> , 38, 178-85	12.3	28
156	Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 391-405	5.1	28
155	Haemophagocytic syndrome and COVID-19. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 1233-1244	3.9	28
154	The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases. <i>Lung</i> , <b>2018</b> , 196, 239-248	2.9	28
153	Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. <i>Lupus</i> , <b>2014</b> , 23, 166-75	2.6	27
152	Chronic hepatitis B virus infection in Sjögren's syndrome. Prevalence and clinical significance in 603 patients. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 616-20	13.6	27
151	Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	27
150	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
149	Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 686-92	2.2	27
148	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2431-2448	4	26
147	Complexity, comorbidity, and health care costs associated with chronic widespread pain in primary care. <i>Pain</i> , <b>2016</b> , 157, 818-826	8	26
146	Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjögren's syndrome. <i>Journal of Internal Medicine</i> , <b>2020</b> , 287, 180-188	10.8	26

145	Hepatitis C virus and Sjögren's syndrome: trigger or mimic?. <i>Rheumatic Disease Clinics of North America</i> , <b>2008</b> , 34, 869-84, vii	2.4	25
144	Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14 Suppl 1, s64-72	2.6	25
143	Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1593-9	4.1	25
142	Bronchiectasis in primary Sjögren's syndrome: prevalence and clinical significance. <i>Clinical and Experimental Rheumatology</i> , <b>2010</b> , 28, 647-53	2.2	25
141	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, S48-52	2.2	25
140	How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 250	5.7	24
139	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , <b>2019</b> , 5, e001064	5.9	24
138	Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features. <i>British Journal of Rheumatology</i> , <b>2002</b> , 41, 670-5		24
137	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2020</b> , 59, 2350-2359	3.9	24
136	White matter abnormalities in primary Sjögren syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2012</b> , 105, 433-43	2.7	23
135	Is hepatitis C virus a sialotropic virus?. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 1593-4	5.8	23
134	Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. <i>Autoimmunity Reviews</i> , <b>2004</b> , 3, 376-82	13.6	22
133	Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. <i>Journal of Viral Hepatitis</i> , <b>2005</b> , 12, 648-54	3.4	22
132	Sarcoidosis Involving the Gastrointestinal Tract: Diagnostic and Therapeutic Management. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1238-1247	0.7	22
131	Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 380-8	2.2	22
130	Abdominal aortic aneurysm screening program using hand-held ultrasound in primary healthcare. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176877	3.7	21
129	Extrahepatic manifestations in patients with chronic hepatitis C virus infection. <i>Current Opinion in Internal Medicine</i> , <b>2005</b> , 17, 447-55		21
128	Splenectomy for refractory Evans' syndrome associated with antiphospholipid antibodies: report of two cases. <i>Annals of the Rheumatic Diseases</i> , <b>2000</b> , 59, 920-3	2.4	21

127	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
126	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
125	Is it time for biosimilars in autoimmune diseases?. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 954-7	13.6	20
124	Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 736-42	3.4	20
123	Severe, life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 121-129	2.2	20
122	Cutaneous lupus erythematosus: clinical and immunological study of 308 patients stratified by gender. <i>Clinical and Experimental Dermatology</i> , <b>2010</b> , 35, 729-35	1.8	19
121	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	19
120	Targeted therapy for systemic sclerosis: how close are we?. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 269-78	7.1	18
119	Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1108, 448-56	6.5	18
118	Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14, 64-72	2.6	18
117	Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE). <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 119, 169-74	6.2	18
116	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
115	How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients. <i>International Immunopharmacology</i> , <b>2015</b> , 27, 194-9	5.8	17
114	Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , <b>2018</b> , 2, 267-276	3.1	17
113	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 875-80	4.1	17
112	Coeliac disease associated with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 104-5	2.4	17
111	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 114-122	2.2	16
110	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15

109	Cytokines as therapeutic targets in primary Sjögren syndrome. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 184, 81-97	13.9	15
108	Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjögren's syndrome. <i>Rheumatology</i> , <b>2009</b> , 48, 65-9	3.9	15
107	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
106	Diagnosis of Liver Involvement in Primary Sjögren Syndrome. <i>Journal of Clinical and Translational Hepatology</i> , <b>2013</b> , 1, 94-102	5.2	15
105	Basophils, IgE, and autoantibody-mediated kidney disease. <i>Journal of Immunology</i> , <b>2011</b> , 186, 6083-90	5.3	14
104	Lessons from diseases mimicking Sjögren's syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2007</b> , 32, 275-83	12.3	14
103	How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , <b>2019</b> , 197, 427-436	2.9	13
102	Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses. <i>PLoS ONE</i> , <b>2014</b> , 9, e84895	3.7	13
101	The DWEYS peptide in systemic lupus erythematosus. <i>Trends in Molecular Medicine</i> , <b>2012</b> , 18, 215-23	11.5	13
100	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13
99	Cryoglobulinemic disease. <i>Oncology</i> , <b>2013</b> , 27, 1098-1105, 1110-6	1.8	13
98	Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1052-1064	2.2	13
97	Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects. <i>Drugs</i> , <b>2016</b> , 76, 1601-1623	12.1	12
96	Phenotyping Sjögren's syndrome: towards a personalised management of the disease. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 198-209	2.2	12
95	Circulating concentrations of soluble L-selectin (CD62L) in patients with primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2000</b> , 59, 297-9	2.4	11
94	Hepatitis G virus infection in primary Sjögren's syndrome: analysis in a series of 100 patients. <i>Annals of the Rheumatic Diseases</i> , <b>1998</b> , 57, 42-4	2.4	11
93	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
92	Lessons from the "Euro-Lupus Cohort". <i>Annales De Médecine Interne</i> , <b>2002</b> , 153, 530-6		10



91	Systemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 69, 77-85	3.9	9
90	OP0217 Defining Disease Activity Sates and Minimal Clinically Important Improvement (MCII) with the EULAR Primary Sjögren's Syndrome Disease Activity Index (ESSDAI). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 144.2-145	2.4	9
89	Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. <i>Revista Española De Sanidad Penitenciaria</i> , <b>2017</b> , 19, 87-97	0.4	9
88	The prevalence of 78 autoimmune diseases in Catalonia (MASCAT-PADRI Big Data Project). <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102448	13.6	9
87	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , <b>2021</b> , 60, 2946-2957	3.9	8
86	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
85	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
84	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
83	Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1085-1101	3.8	6
82	Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 618-20	8.1	6
81	New approaches in Sjögren's syndrome therapy. <i>Expert Review of Clinical Immunology</i> , <b>2007</b> , 3, 195-204	5.1	6
80	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	6
79	Sjögren's Syndrome: Beyond Sicca Involvement <b>2011</b> , 45-65		6
78	Factors influencing dry mouth in patients with primary Sjögren syndrome: usefulness of the ESSPRI index. <i>Oral Health and Dental Management</i> , <b>2014</b> , 13, 402-7	0	6
77	SARS-CoV-2 infection in patients with systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 676-687	2.2	6
76	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
75	Etiopathogenic role of surfactant protein d in the clinical and immunological expression of primary Sjögren syndrome. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 111-8	4.1	5
74	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	5



73	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 208-216	7.5	5
72	Interleukin-4 receptor alpha polymorphisms in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2004</b> , 22, 374	2.2	5
71	Clinical guidelines for the management of acute viral infections in patients with systemic lupus erythematosus. <i>Minerva Medica</i> , <b>2009</b> , 100, 437-46	2.2	5
70	Synthetic pharmacotherapy for pulmonary sarcoidosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1397-1404	4	4
69	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
68	Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. <i>Viruses</i> , <b>2021</b> , 13,	6.2	4
67	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
66	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , <b>2021</b> , 60, 4558-4567	3.9	4
65	Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105236	2.9	4
64	Low values of creatine kinase in systemic lupus erythematosus. Clinical significance in 300 patients. <i>Clinical and Experimental Rheumatology</i> , <b>2002</b> , 20, 837-40	2.2	4
63	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 97-106	2.2	4
62	Granulocytes <b>2014</b> , 201-215		3
61	Clinical characterization and outcomes of 85 patients with neurosarcoidosis. <i>Scientific Reports</i> , <b>2021</b> , 11, 13735	4.9	3
60	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
59	Digestive Involvement in Primary Sjögren's Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 271-292	0.3	2
58	Antiphospholipid syndrome and minimal change nephropathy. <i>Lupus</i> , <b>2006</b> , 15, 547-8	2.6	2
57	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
56	Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. <i>Immunotherapy</i> , <b>2021</b> , 13, 465-475	3.8	2

55	THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) <b>2019</b> ,		2
54	Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 95-102	2.2	2
53	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 57-65	2.2	2
52	SAT0206 Minimally-Invasive Technique for the Biopsy of Minor Salivary Glands: Searching for Systemic Infiltrative Diseases in Patients Presenting with SICCA Symptoms. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 664.2-664	2.4	1
51	Biologics use in sle in 23 centers Data from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A9.1-A9	2.4	1
50	Chapter 16 Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 8, 209-304	0.3	1
49	Autoimmune diseases in the elderly: systemic lupus erythematosus and Sjögren's syndrome. <i>Aging Health</i> , <b>2008</b> , 4, 389-397		1
48	Manifestaciones clínicas e inmunológicas asociadas a la infección crónica por el virus de la hepatitis C. <i>Revista Clinica Espanola</i> , <b>2002</b> , 202, 224-232	0.7	1
47	Systemic Therapy of Sjögren Syndrome. <i>Rare Diseases of the Immune System</i> , <b>2016</b> , 383-398	0.2	1
46	Immunological Tests in Primary Sjögren Syndrome <b>2011</b> , 401-416		1
45	Granulocytes: Neutrophils, Basophils, Eosinophils <b>2020</b> , 243-262		1
44	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 85-94	2.2	1
43	Practical guidelines for the early diagnosis of Sjögren's syndrome in primary healthcare. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 197-205	2.2	1
42	COVID-19 vaccination unveiling subclinical Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 228-229	2.2	1
41	Cardiovascular Involvement in Primary Sjögren's Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 14, 427-441	0.3	0
40	Geoeidemiology of Sarcoidosis <b>2019</b> , 1-21		0
39	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts.. <i>Computational and Structural Biotechnology Journal</i> , <b>2022</b> , 20, 471-484	6.8	0
38	SAT0536 IMMUNE CHECKPOINT INHIBITOR THERAPY IN PATIENTS WITH PREEXISTING SARCOIDOSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1225.2-1226	2.4	0

37	Laboratory Abnormalities in Primary Sjögren Syndrome <b>2011</b> , 347-366		o
36	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , <b>2021</b> , 38, 265-284	4-7	o
35	An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2359-2371	4	o
34	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 166-174	2.2	o
33	OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 175.3-176	2.4	
32	THU0352 Worldwide Heterogeneous Diagnostic Approach To Primary Sjögren Syndrome in 8315 Patients (EULAR-SS Task Force Big Data Sjögren Project). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 314.2-315	2.4	
31	THU0396 IgG4-Related Disease or Primary Sjogren Syndrome? Organ-Specific Involvement and Immunological Profile Are Clues in Differentiating Two Diseases with A Common Clinical Presentation. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 318.3-319	2.4	
30	Primary Biliary Cholangitis. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 13, 83-101	0.3	
29	Extrahepatic Manifestations in Patients With Chronic Hepatitis C Virus Infection. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 13, 173-202	0.3	
28	IgG4-Related Disease: Gastrointestinal Involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 13, 399-410	0.3	
27	THU0408 How we are Treating Our Systemic Patients with Primary Sjögren Syndrome? Analysis of 1120 Patients (GEAS-SS Spanish Registry). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 344.2-344	2.4	
26	Treatment of cryoglobulinemic vasculitis associated with hepatitis C virus infection. <i>Medicina Clínica (English Edition)</i> , <b>2015</b> , 144, 410-417	0.3	
25	THU0283 Two Year Follow-Up on Biologics Use in 13 Centers - Data from the International Registry for Biologics in SLE (IRBIS). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A261.3-A262	2.4	
24	SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A640.2-A641	2.4	
23	Systematic review on the use of adalimumab in autoimmune. Efficacy and safety in 54 patients. <i>Reumatología Clínica (English Edition)</i> , <b>2010</b> , 6, 121-127	0.1	
22	Other Biological Therapies in Primary Sjögren Syndrome <b>2011</b> , 589-598		
21	Punctal occlusion in Sjögren's syndrome needs clarification. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 752-752		
20	Rituximab in SLE <b>2012</b> , 32-41		

19	Classification of fibromyalgia. A systematic review of the literature. <i>Reumatologia Clínica (English Edition)</i> , <b>2009</b> , 5, 55-62	0.1
18	Extrahepatic manifestations in patients with chronic infections due to the hepatitis C virus. <i>Reumatologia Clínica (English Edition)</i> , <b>2009</b> , 5, 71-75	0.1
17	Treatment of Primary Sjögren Syndrome: A Systematic Review. <i>Yearbook of Medicine</i> , <b>2010</b> , 2010, 43-44	
16	Chapter 7 Digestive Involvement in Primary Sjögren's Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 8, 71-81	0.3
15	Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 9, 95-101	0.3
14	Advances in lupus and Sjögren's syndrome: a tribute to Josep Font. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1108, 51-63	6.5
13	Mise à jour des recommandations EULAR sur l'utilisation des thérapies immunomodulatrices dans la prise en charge de la Covid-19. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2021</b> , 88, A214-A215	0.1
12	Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection <b>2008</b> , 301-305	
11	Gastrointestinal Involvement in Primary Sjögren Syndrome <b>2011</b> , 227-235	
10	Primary Sjögren Syndrome in Primary Health Care <b>2011</b> , 501-514	
9	Primary Sjögren Syndrome and Viruses <b>2011</b> , 55-66	
8	Myths, Pearls, and Tips Regarding Sjögren Syndrome <b>2011</b> , 15-34	
7	Life-Threatening Cryoglobulinemia <b>2011</b> , 133-162	
6	Targeting B Cells in Other Systemic Autoimmune Diseases. <i>Milestones in Drug Therapy</i> , <b>2014</b> , 247-258	
5	Systemic Lupus Erythematosus: Indirect B-Cell Blocking. <i>Milestones in Drug Therapy</i> , <b>2014</b> , 79-95	
4	Sialadenitis <b>2021</b> , 48-63	
3	COVID-19 vaccination unveiling subclinical Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> ,	2.2
2	Gene Variation at Immunomodulatory and Cell Adhesion Molecules Loci Impacts Primary Sjögren's Syndrome.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 822290	4.9

- 1 Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 133, 166-174 2.2